Moderna posts bigger loss than expected
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Julie Hyman and Josh Lipton preview the biggest earnings stories and economic data due out tomorrow, Friday, February 14. Pharmaceutical company Moderna (MRNA) and energy provider Enbridge (ENB) are ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
1d
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...
An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...
Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...
Moderna (NASDAQ:MRNA – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.
According to HHS, the funding will enable Moderna to streamline a vaccine that is “well matched to strains currently circulating in cows and birds,” and expand data on the use of mRNA vaccines ...
Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback